Results 61 to 70 of about 12,566,431 (163)

Production of therapeutic levels of human FIX-R338L by engineered B cells using GMP-compatible medium

Molecular Therapy: Methods & Clinical Development, 2023
B cells can differentiate into plasmablast and plasma cells, capable of producing antibodies for decades. Gene editing using zinc-finger nucleases (ZFN) enables the engineering of B cells capable of secreting sustained and high levels of therapeutic ...
Marion David, Davide Monteferrario, Gaëlle Saviane, Caroline Jeanneau, Irène Marchetti, Coralie F. Dupont, Céline Dumont, Jason D. Fontenot, Maurus de la Rosa, David Fenard   +9 more
doaj  

Identification of Novel F9 Gene Variants in 143 Vietnamese Patients with Hemophilia B

Journal of Blood Medicine
Khanh Quoc Bach,1– 3 Chinh Quoc Duong,1,2 Huong Thi Bich Vu,1 Binh Thanh Ngoc Nguyen,1 Trang Thuy Nguyen,1 Mai Thi Nguyen,1 Ruoxin Li,4 Wendy Hutchison,4 Farisha Shabnam Esaq,4 Huyen Tran,5 Thanh Ha Nguyen1,3 1National Institute of Hematology and Blood ...
Bach KQ, Duong CQ, Vu HTB, Nguyen BTN, Nguyen TT, Nguyen MT, Li R, Hutchison W, Esaq FS, Tran H, Nguyen TH   +10 more
doaj  

Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis. [PDF]

Res Pract Thromb Haemost, 2023
Shapiro AD, Chambost H, Ozelo MC, Falk A, Ahlin H, Casiano S, Santagostino E.   +6 more
europepmc   +1 more source

Importancia del diagnóstico de portadoras en familias con antecedentes de hemofilia

Revista Cubana de Hematología, Inmunología y Hemoterapia
La hemofilia es una enfermedad hemorrágica hereditaria ligada al cromosoma X que se presenta debido a mutaciones en los genes del factor VIII (hemofilia A) y el factor IX (hemofilia B), que ocasiona una disminución o deficiencia funcional de estas ...
Kalia Lavaut Sánchez
doaj  

Hemophilia B Gene Therapy with a High‐Specific‐Activity Factor IX Variant

New England Journal of Medicine, 2017
Lindsey A. George, S. Sullivan, A. Giermasz, J. Rasko, B. Samelson-Jones, J. Ducore, A. Cuker, L. Sullivan, S. Majumdar, J. Teitel, C. McGuinn, M. Ragni, A. Luk, Daniel J. Hui, Fraser Wright, Yifeng Chen, Yun Liu, Katie Wachtel, Angela Winters, S. Tiefenbacher, V. Arruda, J. C. M. van der Loo, O. Zelenaia, D. Takefman, M. Carr, L. Couto, X. Anguela, K. High   +27 more
semanticscholar   +1 more source

Sensibilidad del tiempo parcial de tromboplastina activado a la deficiencia de factores VIII y IX Y a la heparina Sensitivity of the activated partial thromboplastin time to the deficiency of factors VIII and IX and heparin

Revista Cubana de Hematología, Inmunología y Hemoterapia, 2001
Se reevaluó el rango de referencia del tiempo parcial de tromboplastina activada (TPTA). Se obtuvo un rango de referencia de 29 a 40 seg. con una media () de 34,01 seg.
Alina Díaz Concepción, Delfina Almagro Vázquez, Alberto Brito Martínez   +2 more
doaj  

"Relation of Factor VIII and IX Inhibitors with ABO Blood Groups in 150 Patients with Haemophilia A and B "

Iranian Journal of Allergy, Asthma and Immunology, 2006
Many investigations have proved relations between ABO blood groups with some diseases and factor VIII and von willebrand level in plasma. In this study we investigated a relation between ABO blood groups and factor VIII and IX inhibitors in 102 patients ...
Hassan Mansouri Torghabeh, Aliakbar Pourfathollah, Mahmood Mahmoodian Shooshtari, Zahra Rezaie Yazdi   +3 more
doaj  

New developments in the management of moderate-to-severe hemophilia B

Journal of Blood Medicine, 2016
Moniba Nazeef,1,2 John P Sheehan1,2 1Department of Medicine, Division of Hematology/Oncology, 2UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA Abstract: Hemophilia B is an X-linked genetic ...
Nazeef M, Sheehan JP
doaj  

Extended Half-Life Factor VIII and Factor IX Preparations

Transfusion Medicine and Hemotherapy, 2018
L. Graf
semanticscholar   +1 more source

Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies

Seminars in Thrombosis and Hemostasis, 2017
S. Kitchen, S. Tiefenbacher, R. Gosselin
semanticscholar   +1 more source